From: Clinical features and death risk factors in COVID-19 patients with cancer: a retrospective study
Clinical features | All patients (n = 309) | Non-cancer patients (n = 206) | Cancer patients (n = 103) | P-value |
---|---|---|---|---|
Age | 66.0 (20.0–95.0) | 66.00 (20.00–95.00) | 66.0 (24.0–90.0) | 0.948 |
Gender | 0.810 | |||
Female | 138 (44.7%) | 91 (44.1%) | 47 (45.6%) | |
Male | 171 (55.3%) | 115 (55.8%) | 56 (54.4%) | |
Comorbidities | ||||
Diabetes | 37 (11.9) | 23 (11.1%) | 14 (13.6%) | 0.579 |
Hypertension | 96 (31.0%) | 59 (28.6%) | 37 (35.9%) | 0.195 |
Heart disease | 41 (13.2) | 30 (14.5%) | 11 (10.7%) | 0.379 |
Symptoms | ||||
Fever | 234 (74.7%) | 161 (78.1) | 73 (70.9%) | 0.163 |
Cough | 207(66.9%) | 137 (66.5%) | 70 (68.0%) | 0.898 |
Dyspnea | 45 (14.6%) | 21 (10.2%) | 24 (23.3%) | 0.003 |
Vomiting | 10 (3.2%) | 5 (2.4%) | 5 (4.9%) | 0.310 |
Diarrhoea | 17 (5.5) | 10 (4.8%) | 7 (6.8%) | 0.597 |
Severity | 0.520 | |||
Non-severe | 209 (67.6%) | 142 (68.9%) | 67 (65%) | |
Severe | 100 (32.4%) | 64 (31%) | 36 (35%) | |
Clinical outcome | 0.028 | |||
Survivor | 288 (93.2%) | 197 (95.6%) | 91 (88.3%) | |
Non-survivor | 21 (6.8%) | 9 (4.4%) | 12 (11.7%) | |
Laboratory findings | ||||
WBC (× 109/L) | 5.50 (0.80–28.20); n = 306 | 5.60 (0.80–28.2); n = 206 | 5.29 (1.90–25.10); n = 100 | 0.381 |
Neutrophil (× 109/L) | 3.25 (0.44–26.07); n = 306 | 3.23 (0.44–26.07); n = 206 | 3.49 (0.67–22.40); n = 100 | 0.164 |
Lymphocyte (× 109/L) | 1.41 (0.60–3.50); n = 306 | 1.54 (0.60–3.50); n = 206 | 1.06 (0.22–2.89); n = 100 | < 0.001 |
NLR | 2.28 (0.20–62.12); n = 306 | 2.11 (0.20–62.12); n = 206 | 2.93 (0.64–32.23); n = 100 | < 0.001 |
Monocytes (× 109/L) | 0.48 (0.03–1.16); n = 278 | 0.50 (0.03–1.16); n = 206 | 0.43 (0.11–1.11); n = 72 | 0.040 |
Eosnophils (× 109/L) | 0.11 (0.00–0.90); n = 278 | 0.12 (0.00–0.72); n = 206 | 0.07 (0.00–0.90); n = 72 | < 0.001 |
Basophils (× 109/L) | 0.03 (0.00–0.11); n = 278 | 0.03 (0.00–0.08); n = 206 | 0.02 (0.00–0.11); n = 72 | 0.076 |
RBC (× 1012/L) | 3.93 (1.17–5.77); n = 279 | 3.93 (1.17–5.60); n = 206 | 3.95 (2.03–5.77); n = 73 | 0.406 |
HB (g/L) | 120.00 (53.00–166.00); n = 279 | 120.50 (53.00–166.00); n = 206 | 116.00 (68.00–154.00); n = 73 | 0.074 |
PLT (× 109/L) | 209.50 (4.00–443.00); n = 278 | 213.00 (4.00–443.00); n = 206 | 203.00 (53.00–431.00); n = 72 | 0.120 |
CRP (mg/L) | 2.27 (0 .01–280.32); n = 251 | 2.16 (0.01–268.60); n = 161 | 2.52 (0.14–280.32); n = 90 | 0.147 |
ALT (U/L) | 21.67 (4.50–239.70); n = 301 | 23.35 (5.30–239.70); n = 204 | 19.17 (4.50–131.20); n = 97 | 0.047 |
AST (U/L) | 21.55 (9.60–502.40); n = 260 | 21.51 (9.60–502.40); n = 176 | 21.70 (10.00–147.20); n = 84 | 0.374 |
Total protein (g/L) | 65.5 (32.70–87.58); n = 276 | 65.81 (32.70–81.6); n = 205 | 64.99 (53.70–87.58); n = 71 | 0.528 |
Albumin (g/L) | 37.30 (18.3–48.00); n = 276 | 37.36 (18.30–45.55); n = 205 | 37.29 (23.60–48.00); n = 71 | 0.723 |
Globulin (g/L) | 27.73 (14.40–46.24); n = 276 | 27.70 (14.40–45.91); n = 205 | 28.00 (17.31–46.24); n = 71 | 0.417 |
A/G | 1.33 (0.39–2.65); n = 276 | 1.33 (0.70–2.65); n = 205 | 1.30 (0.39–2.20); n = 71 | 0.338 |
Total bilirubin (umol/L) | 10.00 (4.20–415.70); n = 274 | 9.76 (4.20–415.70); n = 204 | 10.32 (4.20–44.58); n = 70 | 0.514 |
Direct Bilirubin (umol/L) | 2.50 (0.00–326.70); n = 274 | 2.50 (0.00–326.70); n = 204 | 2.71 (0.00–23.90); n = 70 | 0.412 |
Indirect bilirubin (umol/L) | 7.18 (2.69–89.01); n = 274 | 7.17 (2.69–89.01); n = 204 | 7.39 (2.99–26.42); n = 70 | 0.883 |
BUN (umol/L) | 4.88 (2.23–36.08); n = 272 | 4.93 (2.23–36.08); n = 204 | 4.67 (2.68–29.61); n = 68 | 0.471 |
Creatinine (umol/L) | 60.00 (13.25–345.35); n = 273 | 60.87 (26.77–243.40); n = 203 | 57.72 (13.25–345.35); n = 70 | 0.509 |
Uric acid (umol/L) | 281.63 (69.00–600.56); n = 273 | 286.02 (69.00–600.56); n = 204 | 268.01 (100.00–575.95); n = 69 | 0.274 |
ALP (U/L) | 71.10 (31.90–493.30); n = 272 | 71.12 (31.90–366.10); n = 202 | 71.10 (42.59–493.30); n = 70 | 0.461 |
γ-GT (U/L) | 26.50 (7.64–263.6); n = 273 | 26.50 (7.64–242.2); n = 203 | 26.47 (8.15–263.60); n = 70 | 0.813 |
CK (U/L) | 44.31 (10.90–1210.00); n = 229 | 43.20 (11.00–1210.00); n = 174 | 48.40 (10.90–195.90); n = 55 | 0.084 |
LDH (U/L) | 175.35 (2.17–1489.89); n = 270 | 174.10 (99.90–489.89); n = 201 | 179.90 (2.17–761.70); n = 69 | 0.686 |
ɑ-HBDH (U/L) | 130.30 (79.66–1028.00); n = 267 | 129.80 (79.66–1028.00); n = 201 | 133.59 (87.75–701.40); n = 66 | 0.511 |
D-dimer (mg/L) | 0.44 (0.01−27.94); n = 172 | 0.44 (0.01−6.91); n = 127 | 0.43 (0.02–27.94); n = 45 | 0.498 |
NT-proBNP (U/L) | 43.94 (0.01–35,000.00); n = 102 | 51.61 (0.01–35,000.00); n = 80 | 30.77 (0.01–515.18); n = 22 | 0.503 |
Procalcitonin (ng/ml) | 0.045 (0.01–87.04); n = 200 | 0.042 (0.01–87.04); n = 144 | 0.05 (0.02–0.90); n = 56 | 0.231 |
IL-6 (pg/ml) | 3.20 (1.50–5000.00); n = 189 | 3.0 (1.50–5000.00); n = 139 | 3.64 (1.50–3392.00); n = 50 | 0.099 |